

## Dr. med. Martin Leu

### Publikationen (August 2021)

#### Originalarbeiten

In Zeitschriften:

#### Erst- und Letztautorschaften:

1. **Leu M**, Patzer C, Guhlich M, Possiel J, Pilavakis Y, Schirmer MA, Rieken S, Dröge LH (2021): Postoperative Radiochemotherapy Using Modern Radiotherapy Techniques in Elderly Patients with Head and Neck Squamous Cell Carcinoma: The Challenge of Weighing up Benefits and Harms of Treatment Modalities in Clinical Practice. *Cancers* 13, 3384  
Impact-Faktor 2020: 6,639
2. **Leu M**, Riebeling T, Dröge LH, Hubert L, Guhlich M, Wolff HA, Brockmüller J, Gaedcke J, Rieken S, Schirmer MA (2021): 8-Oxoguanine DNA Glycosylase (OGG1) Cys326 Variant: Increased Risk for Worse Outcome of Patients with Locally Advanced Rectal Cancer after Multimodal Therapy. *Cancers* 13, 2805  
Impact-Faktor 2020: 6,639
3. Possiel J, Ammon HE, Guhlich M, Conradi L-C, Ghadimi M, Wolff HA, Schirmer MA, Samel S, Mügge M, Rieken S, **Leu M\***, Dröge LH\* (2021): Volumetric Modulated Arc Therapy Improves Outcomes in Definitive Radiochemotherapy for Anal Cancer Whilst Reducing Acute Toxicities and Increasing Treatment Compliance. *Cancers* 13, 2533  
\*Geteilte Letztautorschaft  
Impact-Faktor 2020: 6,639
4. Dröge LH, Karras PJ, Guhlich M, Schirmer MA, Ghadimi M, Rieken S, Conradi L-C, **Leu M** (2021): Preoperative Radiochemotherapy in Esophageal Squamous Cell Cancer with 5-Fluorouracil/Cisplatin or Carboplatin/Paclitaxel: Treatment Practice over a 20-Year

Period and Implications for the Individual Treatment Modalities. *Cancers* 13, 1834

Impact-Faktor 2020: 6,639

5. **Leu M**, Kitz J, Pilavakis Y, Hakroush S, Wolff HA, Canis M, Rieken S, Schirmer MA (2021): Monocarboxylate transporter-1 (MCT1) protein expression in head and neck cancer affects clinical outcome. *Sci Rep* 11, 4578

Impact-Faktor 2020: 4.379

6. **Leu M**, Possiel J, Schirmer MA, Hille A, Rieken S, Dröge LH (2020): Evaluation of Prognosticators and Treatment-Related Side Effects in Patients Irradiated Postoperatively for Endometrial Cancer. *Cancers* 12, 3613

Impact-Faktor 2020: 6,639

7. Schirmer MA\*, Beck J\*, **Leu M\***, Oellerich M, Rave-Fränk M, Walson PD, Schütz E, Canis M (2018): Cell-Free Plasma DNA for Disease Stratification and Prognosis in Head and Neck Cancer. *Clin Chem* 64, 959–970

\*Geteilte Erstautorschaft

Impact-Faktor 2018: 6,916

8. Beschel LM\*, **Leu M\***, Reichardt SD, Rave-Fränk M, Schirmer MA, Stadelmann C, Canis M, Wolff HA, Reichardt HM (2016): T cell abundance in blood predicts acute organ toxicity in chemoradiotherapy for head and neck cancer. *Oncotarget* 7, 65902–65915

\*Geteilte Erstautorschaft

Impact-Faktor 2016: 5,168

9. **Leu M**, Wiesemann C (2015): Die Professionalisierung der Medizinethik in Deutschland nach 1945: Zur Frühgeschichte der Zeitschrift *Arzt und Christ*. *Z. Med. Ethik* 61, 283–301

Kein Impact-Faktor ausgewiesen

## Ko-Autorschaften:

1. Jakob M, Sharaf K, Schirmer M, Leu M, Küffer S, Bertlich M, Ihler F, Haubner F, Canis M, Kitz J (2021): Role of cancer stem cell markers ALDH1, BCL11B, BMI-1, and CD44 in the prognosis of advanced HNSCC. *Strahlenther Onkol* 197, 231–245  
Impact-Faktor 2020: 3,621
2. Bergau PFL, Schirmer MA, Leha A, **Leu M**, Emons G, Hess CF, Hille A (2020): The impact of rectal/bladder filling and applicator positioning on in vivo rectal dosimetry in vaginal cuff brachytherapy using an enhanced therapy setting. *Brachytherapy* 19, 168–175  
Impact-Faktor 2020: 2,362
3. Baumeister P, Hollmann A, Kitz J, Afthonidou A, Simon F, Shakhtour J, Mack B, Kranz G, Libl D, **Leu M**, Schirmer MA, Canis M, Belka C, Zitzelsberger H, Ganswindt U, Hess J, Jakob M, Unger K, Gires O (2018): High Expression of EpCAM and Sox2 is a Positive Prognosticator of Clinical Outcome for Head and Neck Carcinoma. *Sci Rep* 8, 14582  
Impact-Faktor 2018: 4,011
4. Rave-Fränk M, Tehrany N, Kitz J, **Leu M**, Weber HE, Burfeind P, Schliephake H, Canis M, Beissbarth T, Reichardt HM et al. (2016): Prognostic value of CXCL12 and CXCR4 in inoperable head and neck squamous cell carcinoma. *Strahlenther Onkol* 192, 47–54  
Impact-Faktor 2016: 2,735
5. Dröge LH, Weber HE, Guhlich M, Leu M, Conradi L-C, Gaedcke J, Hennies S, Herrmann MK, Rave-Fränk M, Wolff HA (2015): Reduced toxicity in the treatment of locally advanced rectal cancer: a comparison of volumetric modulated arc therapy and 3D conformal radiotherapy. *BMC Cancer* 15, 750  
Impact-Faktor 2015: 3,265

## Vorträge

1. Leu M (2018): Common genetic variability in TGFB1 and TGFBR1 in relation to radiotoxicity in patients with head and neck cancers, gehalten am 23.06.18, Leipzig, 24. Jahrestagung der Deutschen Gesellschaft für Radioonkologie
2. Leu M (2017): Genotypisierung zell-freier DNA als Biomarker für die personalisierte Therapie bei Kopf-Hals-Karzinomen (HNSCC), gehalten am 17.06.17, Berlin, 23. Jahrestagung der Deutschen Gesellschaft für Radioonkologie
3. Leu M (2016): Immunhistochemische Expression von Monocarboxylase-Transportern (MCTs) und Überleben nach definitiver Radiochemotherapie (RCT) bei Kopf-Hals-Karzinomen (HNSCC), gehalten am 18.06.16, Mannheim, 22. Jahrestagung der Deutschen Gesellschaft für Radioonkologie